Effects of SCH 34826, an orally active inhibitor of atrial natriuretic peptide degradation, in healthy volunteers.
Burnier M., Ganslmayer M., Perret F., Porchet M., Kosoglou T., Gould A., Nussberger J., Waeber B., Brunner H.R., 1991. Clinical pharmacology and therapeutics, 50 (2) pp. 181-91. Peer-reviewed.
ici le détail